[ad_1]
STOCKHOLM, March 4, 2022 /PRNewswire/ — BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401). The lecanemab Clarity AD Phase 3 clinical study for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) is ongoing.
The PMDA’s process, known as “prior assessment consultation”, is conducted at the development stage before the new drug application submission, which is based on available quality, non-clinical and clinical data. By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.
Based on discussions with the Ministry of Health, Labour and Welfare (MHLW) and PMDA, Eisai applied to PMDA for permission to utilize the “prior assessment consultation” process for lecanemab with the aim of shortening the review period. The agency approved Eisai’s request and Eisai has submitted the non-clinical lecanemab data to PMDA. The additional data of the application package will be submitted hereafter. Eisai plans to obtain the primary endpoint data from Clarity AD study in the fall of 2022, and based on the results of the study , aims to file for the manufacturing and marketing approval in Japan before end of March 2023.
In September 2021Eisai initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab, an investigational agent under the Accelerated Approval pathway for the treatment of early AD with confirmed amyloid pathology, and expects to complete this rolling submission in the second quarter 2022. Based on the results of the confirmatory Clarity AD study, Eisai plans to submit for full approval of lecanemab to the US FDA before end of March 2023.
This release discusses investigational uses of an agent in development and is not intended to convey …
Full story available on Benzinga.com
[ad_2]
Source link